Figure 9
(A) Immunohistochemistry data showing alpha smooth muscle actin (αSMA) expression in a mouse model of TGFβ-induced lung fibrosis. The animals were challenged with adenoviral vector encoding TGFβ (6 × 106 pfu) and orally treated with vehicle (dH2O), esomeprazole (30 mg/kg), pirfenidone (100 mg/kg) or esomeprazole (30 mg/kg) and pirfenidone (100 mg/kg) combination as described in the “Materials and methods” section. The data shows that the combination therapy inhibits lung tissue muscularization, as shown by reduced αSMA expression (brown stain), more effectively that the monotherapy (arrows). In panel (B), zoomed out images of the tissue included in the analysis are shown. The semi-quantitative scores are shown in the table and the data is representative of 5 animals/group.
